Bone disease in myeloma

Current Treatment Options in Oncology

Volumn 2, Issue 3, 2001, Pages 271-283

  Berenson, James R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone Resorption; Multiple Myeloma; Myeloma; Pamidronate; Zoledronic Acid

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE;

BONE DISEASE; HUMAN; MULTIPLE MYELOMA; PATHOLOGY; RADIOTHERAPY; REVIEW;

ANTINEOPLASTIC AGENTS; BONE DISEASES; DIPHOSPHONATES; HUMANS; MULTIPLE MYELOMA; RADIOTHERAPY;

EID: 0035382552     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-001-0041-5     Document Type: Article

References (75)

1. Mundy GR, Bertoline DR: Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 1986, 13:291–299.
2. Belch AR, Bergsagel DE, Wilson K, et al.: Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991, 9:1397–1402.
3. Kyle RA, Jowsey J, Kelly PJ, et al.: Multiple myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo. N Engl J Med 1975, 293:1334–1338. DOI: 10.1056/NEJM197512252932602
4. Kyle RA: Multiple myeloma, review of 869 cases. Mayo Clin Proc 1975, 50:29–40.
5. Stashenko P, Dewhirst FE, Peros WJ, et al.: Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol 1987, 138:1464–1468.
6. Mundy GR: Mechanisms of osteolytic bone destruction. Bone 1991, 12(suppl):S1-S6. DOI: 10.1016/8756-3282(91)90057-P
7. Bataille R, Chappard D, Basle M: Excessive bone resorption in human plasmacytomas: direct induction by tumor cells in vivo. Br J Haematol 1995, 90:721–724.
8. Berenson JR, Lipton A: Bisphosphonates in the treatment of malignant bone disease. Annu Rev Med 1999, 50:237–248. This article reviews clinical trials involving bisphosphonates in the treatment of bone metastases. DOI: 10.1146/annurev.med.50.1.237
9. Kanis JA, McCloskey EV, Taube T, et al.: Rationale for the use of bisphosphonates in bone metastases. Bone 1991, 12(suppl):S13-S18. DOI: 10.1016/8756-3282(91)90061-M
10. Fleisch H: Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. In Recent Results in Cancer Research, Vol. 116: Bisphosphonates and Tumor Osteolysis. Edited by Brunner KW, Fleisch H, Senn H-J. Berlin: Springer-Verlag; 1989:12–28.
11. Lahtinen R, Laakso M, Palva I, et al.: Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992, 340:1049–1052. DOI: 10.1016/0140-6736(92)93075-X
12. Man Z, Otero AB, Rendo P, et al.: Use of pamidronate for multiple myeloma osteolytic lesions. Lancet 1990, 335:663. DOI: 10.1016/0140-6736(90)90452-B
13. Thiebaud D, Leyuraz S, Von Fliedner V, et al.: Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 1991, 27:37–41. DOI: 10.1016/0277-5379(91)90056-J
14. Purohit OP, Anthony C, Radstone CR, et al.: High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994, 70:554–558.
15. van Holten-Verzantvoort AATM, Kroon HM, Bijvoet OLM, et al.: Palliative treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11:491–498.
16. McCloskey EV, MacLennan CM, Drayson MT, et al.:A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998, 101:317–325. DOI: 10.1046/j.1365-2141.1998.00567.x
17. Heim ME, Clemens MR, Queisser W, et al.:Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment. A multicenter study. Onkologie 1995, 18:439–448. DOI: 10.1159/000218633
18. Brincker H, Westin J, Abildgaard U, et al.: Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Br J Haematol 1998, 101:280–286. DOI: 10.1046/j.1365-2141.1998.00695.x
19. Berenson JR, Lichtenstein A, Porter L, et al.: Efficacy of pamidronate in reducing the skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996, 334:488–493. DOI: 10.1056/NEJM199602223340802
20. Berenson J, Lichtenstein A, Porter L, et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998, 16:593–602.
21. Rowell NP, Tobias JS: The role of radiotherapy in the management of multiple myeloma. Blood Rev 1991, 5:84–89. DOI: 10.1016/0268-960X(91)90039-F
22. Rostom AY: A review of the place of radiotherapy in myeloma with emphasis on whole body irradiation. Hematol Oncol 1988, 6:193–198. DOI: 10.1002/hon.2900060221
23. Giles FJ, McSweeney EN, Richards JDM, et al.:Prospective randomised study of double hemibody irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma. Eur J Cancer 1992, 28A:1392–1395. DOI: 10.1016/0959-8049(92)90527-9
24. Giralt S, Champlin R, Goodman M, et al.: Preliminary results of a phase I/II study of multiple myeloma (MM) patients treated with 166holmium-DOTMP in combination with high dose melphalan +/- total body irradiation (TBI) with autologous stem cell transplant (ASCT). Blood 2000, 96:558a.
25. Cohen HJ, Silberman HR, Tornyos K, et al.: Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma. Blood 1984, 63:639–648.
26. Acute Leukemia Group B, Eastern Cooperative Oncology Group B: Ineffectiveness of fluoride therapy in multiple myeloma. N Engl J Med 1972, 286:1283–1288. DOI: 10.1056/NEJM197206152862402
27. Warrell RP, Lovett D, Dilmanian A, et al.: Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study. J Clin Oncol 1993, 11:2443–2450.
28. Major P, Lortholary A, Hon J, et al.: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001, 19:558–567. This clinical trial provides the first clear data showing the superiority of a third-generation bisphosphonate over pamidronate.
29. Fleisch H: Bisphosphonates: mechanisms of action. Endocr Rev 1998, 19:80–100. An excellent review of the mechanisms of action of bisphosphonates. DOI: 10.1210/er.19.1.80
30. Aparicio A, Gardner A, Tu Y, et al.: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998, 12:220–229. DOI: 10.1038/sj.leu.2400892
31. Shipman CM, Croucher PI, Russell GG, et al.: The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998, 58:5294–5297.
32. Luckman SP, Hughes DE, Coxon FP, et al.: Nitrogencontaining bisphosphonates inhibit the mevalonic pathway and prevent post-translational prenylation of GTP-binding proteins, including ras. J Bone Miner Res 1998, 13:581–589. DOI: 10.1359/jbmr.1998.13.4.581
33. Reinholz GG, Getz B, Pederson L, et al.: Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000, 60:6001–6007.
34. Savage AD, Belson DJ, Vescio RA, et al.: Pamidronate reduces IL-6 production by bone marrow stroma from myeloma patients. Blood 1996, 88:105a.
35. Derenne S, Amiot M, Barille S, et al.: Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMp-1 by the tumoral environment. J Bone Miner Res 1999, 14:2048–2056. DOI: 10.1359/jbmr.1999.14.12.2048
36. Giuliani N, Pedrazzoni M, Passeri G, et al.: Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 1998, 27:38. DOI: 10.1080/030097498441155
37. Wood J, Schnell C, Green J: Zoledronic acid (Zometa), a potent inhibitor of bone resorption, inhibits proliferation and induces apoptosis in human endothelial cells in vitro and is anti-angiogenic in a murine growth factor implant model. Proc Am Soc Clin Oncol 2000, 19:664a.
38. Singhal S, Mehta J, Desikan R, et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565–1561. DOI: 10.1056/NEJM199911183412102
39. Kunzmann V, Bauer E, Feurle J, et al.: Stimulation of gdT cells by aminobisphosphonate and induction of antiplasma cell activity in multiple myeloma. Blood 2000, 96:384–392.
40. Radl J, Croese JW, Zurcher C, et al.: Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer 1985, 55:1030–1040. DOI: 10.1002/1097-0142(19850301)55:5<1030::AID-CNCR2820550518>3.0.CO;2-Y
41. Yaccoby S, Barlogie B, Epstein J: Pamidronate inhibits growth of myeloma in vivo in the SCID-hu system. Blood 1998, 92:106a.
42. Yaccoby S, Pearse R, Epstein J, et al.: Reciprocal relationship between myeloma-induced changes in the bone marrow microenvironment and myeloma cell growth. Blood 2000, 96:549a.
43. Dallas SL, Garrett IR, Oyajobi BO, et al.: Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 1999, 93:1697–1706.
44. Delmas PD, Charhon S, Chapuy MC, et al.: Long-term effects of dichloromethylene diphosphonate (C12MDP) on skeletal lesions in multiple myeloma. Metabolic Bone Dis Related Res 1982, 4:163–168. DOI: 10.1016/0221-8747(82)90013-3
45. Merlini G, Parrinello GA, Piccinini L, et al.: Long-term effects of parenteral dichloromethylene bisphosphonate (C12MDP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol 1990, 90:2127–2147.
46. Ravn P, Bidstrup M, Wasnich RD, et al.: Alendronate and estrogen-progestin the long-term prevention of bone loss: four-year results from the early postmenopausal osteoporosis intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999, 131:935–942.
47. Berenson J, Rosen L, Vescio R, et al.: Pharmacokinetics of pamidronate disodium in cancer patients with normal and impaired renal dysfunction. J Clin Pharmacol 1997, 37:285–290.
48. Muhlbacher RC, Bauss F, Schenk R, et al.: BM.21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991, 6:1003. DOI: 10.1002/jbmr.5650060915
49. Green JR, Muller K, Jaeggi KA: Preclinical pharmacology of CGP 42’446, a new, potent heterocyclic bisphosphonate compound. J Bone Miner Res 1994, 9:745–750.
50. Percherstorfer M, Herrmann Z, Body JJ, et al.: Randomized phase II trial comparing different doses of the bisphosphonate idbandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996, 14:268–276.
51. Body JJ, Lortholary A, Romieu G, et al.: A dose-finding study of Zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999, 14:1551–1661. DOI: 10.1359/jbmr.1999.14.9.1557
52. Berenson J, Vescio R, Henick K, et al.: A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 2001, 91:144–154. DOI: 10.1002/1097-0142(20010101)91:1<144::AID-CNCR19>3.0.CO;2-Q
53. Berenson J, Vescio R, Rosen L, et al.: A phase I doseranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 2001, In press.
54. Berenson J, Rosen LS, Howell A, et al.: Zoledronic acid reduces skeletal related events in patients with osteolytic metastases: a double-blind, randomized dose-response study. Cancer 2001, In press.
55. Fontana A, Hermann Z, Menssen HD, et al.: Effects of intravenous ibandronate therapy on skeletal related events (SRE) and survival inpatients with advanced multiple myeloma. Blood 1998, 92:106a.
56. Hofbauer LC: Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Soc Eur J Endocrinol 1999, 141:195–210. This article provides a review of the RANK, RANK ligand, and OPG molecules. DOI: 10.1530/eje.0.1410195
57. Altamirano CV, Ma HJ, Parker KM, et al.: RANKL is expressed in malignant multiple myeloma (MM) cell lines. Blood 2000, 96:365a.
58. Shipman CM, Holen I, Lippitt JM, et al.: Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL. Blood 2000, 96:360a.
59. Capparelli C, Kostenuik PJ, Morony S, et al.:Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000, 60:783–787.
60. Honore P, Luger NM, Sabino MAC, et al.: Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000, 6:521–528. DOI: 10.1038/74999
61. Pearse RN, Sordillo EM, Yaccoby S, et al.: Administration of TRANCE-antagonist TR-Fc limits myeloma-induced bone destruction. Blood 2000, 96:549a.
62. Iotsova V, Caamano J, Loy J, et al.: Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997, 11:1285–1289. DOI: 10.1038/nm1197-1285
63. Andela VB, Schwarz EM, Puzas E, et al.: Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kB. Cancer Res 2000, 60:6557–6562.
64. Stinchcombe TE, Mitchell BS, Depcik-Smith N, et al.:PS-341 is active in multiple myeloma: preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies. Blood 2000, 96:516a.
65. Mundy G, Garrett R, Harris S, et al.: Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946–1949. This preclinical study suggests the possible usefulness of statins in increasing bone density. DOI: 10.1126/science.286.5446.1946
66. Service RF: Tissue engineers build new bone. Science 2000, 289:1498–1499. DOI: 10.1126/science.289.5484.1498
67. Engleman VW, Nickols GA, Ross FP, et al.: A peptidomimetic antagonist of the avb3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest 1997, 99:2284–2292.
68. Carron CP, Myer DM, Engleman VW, et al.: Peptidomimetic antagonist of aVb3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone. J Endocrinol 2000, 165:587–598. DOI: 10.1677/joe.0.1650587
69. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569. DOI: 10.1126/science.7512751
70. Brooks PC, Stromblad S, Klemke R, et al.: Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995, 96:1815.
71. Ray J, Stetler-Stevenson W: Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 1995, 14:908.
72. Yoneda T, Sasaki A, Dunstan C, et al.: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997, 99:2509–2517. DOI: 10.1172/JCI119435
73. Vacca A, Ribatta D, Preta M, et al.: Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93:3064–3073.
74. Silletti S, Kessler T, Goldberg J, et al.: Disruption of matrix metalloproteinase 2 binding to integrin aVb3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Nat Acad Sci U S A 2001, 98:119–124. DOI: 10.1073/pnas.011343298
75. Schwartzberg PL, Xing L, Hoffmann O, et al.: Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/-mutant mice. Genes Dev 1997, 11:2835–2834.